UroMems
Specialist Medical Practices · Electrical & Electronic Engineering
$124.3Mtotal raised · 4 rounds on record
$60Mlatest round · Venture round · May 2026 · 6 mo ago
2backers · b2venture, Supernova Invest
$2.7Mgrants · 1 grant · CORDIS
Overview
UroMems is developing breakthrough, automated technology to treat stress urinary incontinence (SUI) providing an improved quality of life for women and men.
Funding and backers
Total raised
$124.3M
4 rounds on record
Latest round
$60M
Venture round · May 2026 · 6 mo ago
Team
11-50
employees, estimated range
Grants
$2.7M
1 grant · CORDIS
Backers
2
b2venture, Supernova Invest
The money's age
Fresh money
6 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 13
Raised a round Venture round $60M
Aug 25, 2025
Launched UroMems Launches Pivotal Trial of Implant to Treat Stress Urinary Incontinence in Men · mddionline.com
Nov 26, 2024
Board appointment UroMems Appoints Former Axonics Executive Rinda Sama to Board of Directors · uromems.com
Jun 25, 2024
Raised a round Series C $47M · PRNewswire
Jul 1, 2023
Won a grant $2.7M · CORDIS
May 20, 2020
Raised a round Venture round $17.3M
Feb 2011
Website went live first capture in the Wayback Machine
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | May 2026 | $60M | — | uromems.com |
| Series C | Jun 2024 | $47M | — | PRNewswire |
| Grant | Jul 2023 | $2.7M | — | CORDIS |
| Venture round | May 2020 | $17.3M | — | markets.businessinsider.com |
Founders and leadersfrom filings, registers and the company's site
Clinical AdvisorsDirectorscompany's site
Backed byfrom the funds' portfolios and accelerator catalogs
b2venture 
Supernova Invest Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Urologic Design is developing a discreet, non-surgical option for men living with stress urinary incontinence.
-Our Mission 誰もが空の恩恵を享受できる世界を実現する トラジェクトリーは、管制の自動化を通じて、誰もが安全かつ簡単に無人航空機の恩恵を享受できる社会を実現し、人々のQOL（Quality of Life）の向上に貢献するというミッションを掲げています。.
Paloma offers a new way to treat and monitor hypothyroidism. Get your blood tests, medical guidance and prescriptions online from the best…
Disposable incontinence briefs with smart inlay technology and real-time alerts. For the better management of urinary incontinence and…
We specialize in transforming men's and women's health through Testosterone Replacement Therapy (TRT), Hormone Replacement Therapy, and…
Medical Device Developmentto Enhance the Quality of Life. 再生医療機器開発.
People
Clinical Advisors
Directors
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
UroMems eyes regulatory filings for SUI treatment after $60m fundraise
UroMems plans to use the funds to complete a pivotal trial to support regulatory filings for its UroActive system in the US and Europe.
Read more
Report
UroMems: $60 Million Raised For Smart Implant Treating Stress Urinary Incontinence
UroMems announced a $60 million strategic investment from Ajax Health to continue funding pivotal clinical trials and commercial launch preparation for the UroActive System, the company's smart automated implant designed to treat stress urinary incontinen
Read more
Report
UroMems Raises $60 Million Strategic Investment from U.S.-Based Ajax Health Fund I
Capital will continue funding pivotal clinical trials and commercial launch preparation of the UroActive System, the first smart automated implant to treat stress urinary incontinence GRENOBLE, France & MINNEAPOLIS, Minn. (May 13, 2026) - UroMems, a globa
Read more
Report
Electronic Artificial Sphincter Device for Stress Urinary Incontinence Shows Early Promise
The post Electronic Artificial Sphincter Device for Stress Urinary Incontinence Shows Early Promise appeared first on UroMems.
Read more
Report
Hamid Lamraoui interview with Medical Device and Diagnostic Industry
READ THE ARTICLE The post Hamid Lamraoui interview with Medical Device and Diagnostic Industry appeared first on UroMems.
Read more
Report
Report
UroMems Receives Clearance from the FDA and the French ANSM for Initiating Landmark Pivotal Clinical Study of UroActive Smart Implant to Treat Male Stress Urinary Incontinence
IDE approval in both countries follows strong feasibility clinical results in France GRENOBLE, France & MINNEAPOLIS, Minnesota (July 17, 2025) - UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence
Read more
Report
Professor CHARTIER-KASTLER interview discussing first-in-woman clinical results
"Now, at 1 year, the 1-hour pad test has been done again, as it's part of the protocol, and she suffered 4 g of incontinence on this test, opposed to 125 g at the beginning," says Emmanuel Chartier-Kastler, MD, PhD. WATCH THE VIDEO The post Professor CHAR
Read more
Report
UroMems Announces Successful Results in First-Ever Female Clinical Feasibility Study of UroActive Smart Implant for Stress Urinary Incontinence Treatment
One-year data for the first patient will be presented for the first time during the SUFU meeting in Palm Springs, Calif.; the promising results demonstrate proof of feasibility in female patients GRENOBLE, France and MINNEAPOLIS, Feb. 20, 2025 /PRNewswire
Read more
Report
UroMems Announces Successful Results in First-Ever Female Clinical Feasibility Study of UroActive Smart Implant for Stress Urinary Incontinence Treatment
UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that the entire treatment cohort in the first-of-its-kind clinical feasibility study in female patients has successfully r
Read more
Report
Show more news